India-based Enzene, a leading global continuously innovative development and manufacturing organisation (CIDMO), has inaugurated a state-of-the-art biomanufacturing facility in Hopewell, New Jersey — its first major manufacturing investment in the United States.

The 80,000-square-foot site marks a significant milestone in the company’s global expansion and is designed to strengthen pharmaceutical innovation and supply chain resilience across North America. The facility includes 26,000 square feet of drug substance manufacturing suites, laboratories, storage, dispensing and warehousing.

In addition to fed-batch drug substance manufacturing, the site makes extensive use of the company’s modular EnzeneX 2.0 platform – the world’s first fully-connected continuous manufacturing (FCCM) technology. According to the company, the sustainable and scalable system, powered by optimised cell media and process analytical technology (PAT), delivers up to 10 times the yield of conventional biomanufacturing while reducing cost of goods sold (COGS) to as low as USD 40 per gram.

New Jersey Governor Phil Murphy, who inaugurated the facility on September 3, 2025, welcomed Enzene’s decision to establish its US base in the state.

He said, “When Enzene — one of India’s most promising biotechnological companies — decided to launch its very first US manufacturing base, they knew there was nowhere better to do it than right here in New Jersey. Their decision reflects not only our state’s strength as a hub for global business and innovation, but also the deep cultural ties that bind New Jersey and India.”

“This state-of-the-art facility represents the future of advanced manufacturing — ultimately creating hundreds of jobs and generating USD 50 million in investment. As Enzene expands its presence here in New Jersey, we remain committed to supporting the company as it builds the world-class manufacturing ecosystem of tomorrow,” he added.

Enzene CEO Himanshu Gadgil said the new site will work in tandem with its Indian facilities to deliver global supply solutions.

“Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high-yield, US-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions,” he said.

Sandeep Singh, Chairman of the Board at Enzene and Managing Director of Alkem Laboratories, called the project a strategic step in the company’s global growth.

“This latest step in the company’s strategic expansion plans extends Enzene’s commitment to providing equitable access to cost-effective manufacturing for early-stage biologics developers in the US and beyond,” he stated.

Enzene operates fully integrated sites in Pune (India) and New Jersey (USA), offering end-to-end CDMO services from discovery and development to commercial supply. The company is targeting monoclonal antibody production costs below USD 40 per gram by 2025.